Treace Medical Concepts (TMCI) Depreciation & Amortization (CF) (2020 - 2026)

Treace Medical Concepts (TMCI) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $899000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 63.47% year-over-year to $899000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (up 1.0% YoY) and the FY2025 annual result came in at $10.6 million, up 26.18% from the prior year.
• Depreciation & Amortization (CF) slipped to $899000.0 in Q1 2026, from $2.8 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.8 million in Q4 2025 to a low of $334000.0 in Q1 2022.
• A 5-year average of $1.6 million and a median of $1.8 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 300.0% — and 2026, when it plunged 63.47%.
• Tracing TMCI's Depreciation & Amortization (CF) over 5 years: stood at $917000.0 in 2022, then surged by 92.91% to $1.8 million in 2023, then rose by 26.46% to $2.2 million in 2024, then rose by 25.53% to $2.8 million in 2025, then tumbled by 67.98% to $899000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $899000.0 (Q1 2026), $2.8 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.